State Ledger
Company profile

Drugs Made In America Acquisition Corp. CIK 2028614

Tickers
DMAA (Nasdaq) · DMAAR (Nasdaq) · DMAAU (Nasdaq)
Industry
Blank Checks
Headquarters
New York, NY 10170
Fiscal year end
2025 (FY)
Market Data
Close
$10.86
Change
+$0.01
Change %
0.05%
Volume
100

DMAA · trading date Oct 12, 2026 · previous close $10.85 · source: Alpaca (IEX feed, not consolidated full-market data).

Key Financials
Revenue
—
Net income
$5.94M
Total assets
$239.92M
Total liabilities
$7.28M
Stockholders' equity
-$7.26M
Cash & equivalents
$6.1K
Operating income
-$2.82M
Operating cash flow
-$539.2K
Capital expenditures
—

Fiscal year 2025, via 10-K filed 2026-04-15. A dash means this figure wasn't reported in the source filing under a field State Ledger recognizes - not that the value is zero.

Financial Performance
Operating margin
—
Net margin
—
Free cash flow
—
Free cash flow margin
—
Liabilities / assets
3.0%
Equity / assets
-3.0%
CapEx / revenue
—
Operating cash flow / net income
-0.09×

Derived from the fiscal year 2025 figures above. These metrics are mathematical calculations and do not represent a rating or assessment of the company.

Financial History
Fiscal yearRevenueNet incomeAssetsLiabilitiesEquity
2025 — $5.94M $239.92M $7.28M -$7.26M
2024 — — $550.8K $795.7K -$244.8K
Company Details
SIC code
6770
Active filer
Yes
Most recent SEC filing
Form 425
2026-09-14
Financials filed via
Form 10-K
filed 2026-04-15

"Most recent SEC filing" may differ from the filing used for the financial figures above.

Location
New York, NY 10170
420 LEXINGTON AVENUE
Data & Methodology

SEC EDGAR submissions API (identity, collected Sep 19, 2026, 15:11 UTC) and SEC XBRL Company Facts API (financials, collected Sep 26, 2026, 15:46 UTC) · figures as originally filed, not restated · a dash always means a value wasn't reported, never a real zero.

← Back to New York — Public Companies